Latest News

Stay up to date with the latest developments in myasthenia gravis research, advocacy, and community support. Explore news, events, and policy updates to stay informed and get involved.

Browse our categories to explore stories relevant to you, and stay connected with the MG community.

All
  • All
  • About MAA News Items
  • Annual Conference News Items
  • Art With Heart News Items
  • Get Involved News Items
  • Health Professionals News Items
  • Living with MG News Items
  • MG Awareness Month News Items
  • Patient Tool Kit
  • Policy Makers News Items
  • Understanding MG News Items
3.-PBAC-Submission-Rozanolixizumab-1024x734 (1)
PBAC submissions for Rystiggo® (Rozanolixizumab) for all Myasthenia Gravis patients
2.-PBAC-Submission-Efgartigimod-1024x734
PBAC submissions for Vyvgart® (efgartigimod alfa) for all Myasthenia Gravis patients
1.-PBAC-Submission-Ravulizumab-and-Zilucoplan-1024x734
PBAC resubmissions for Ultomiris® (Ravulizumab) and Zilbrysq® (Zilucoplan) for all Myasthenia Gravis patients
PBAC-Time-to-Act
It is time to act! The PBAC lists 4 new gMG treatments for consideration at the March 2025 meeting!
HTA and PBAC
HTA and PBAC? What/who are they and what does it mean for us?
MAA-PBAC-Webinar-Featured-Image-Postponed
POSTPONED: Myasthenia Alliance Australia PBAC Submission Update Webinar
MAA PBAC Webinar Featured Image
Myasthenia Alliance Australia PBAC Submission Update Webinar
PBAC-Decision
PBAC Decision: New MG Medications Not Recommended, But Advocacy Efforts Continue
canada-feat-image
Research-Report